Yuzhong Yu
Guangzhou, 510900, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Hsa_circ_0003258 drives serine biosynthesis and docetaxel resistance in prostate cancer by enhancing IGF2BP3-mediated PSAT1 mRNA stability.
Journal: Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy
Published: March 30, 2026
Correction: ELOVL2 mediated stabilization of AR contributes to enzalutamide resistance in prostate cancer.
Journal: Frontiers in cell and developmental biology
Published: June 13, 2025
ELOVL2 mediated stabilization of AR contributes to enzalutamide resistance in prostate cancer.
Journal: Frontiers in cell and developmental biology
Published: March 23, 2025
Efficacy and safety of antibody-drug conjugates in the treatment of advanced urological cancers: a systematic review and a meta-analysis.
Journal: Frontiers in pharmacology
Published: February 26, 2025
Abiraterone, Orteronel, Enzalutamide and Docetaxel: Sequential or Combined Therapy?
Journal: Frontiers in pharmacology
Published: December 24, 2021
Execution of aggregation-induced emission as nano-sensors for hypochlorite detection and application for bioimaging in living cells and zebrafish.
Journal: Talanta
Published: November 11, 2019
Synthesis and pharmacological evaluation of naftopidil-based arylpiperazine derivatives containing the bromophenol moiety.
Journal: Pharmacological reports : PR
Published: July 07, 2019
Fabrication of a hyaluronic acid conjugated metal organic framework for targeted drug delivery and magnetic resonance imaging.
Journal: RSC advances
Published: December 01, 2017
Showing 1-8 of 8
Last Updated: 09/26/2026